Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419) - Archive ouverte HAL
Article Dans Une Revue European Journal of Cancer Année : 2023

Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Caroline Hertler (1, 2) , Jörg Felsberg (3, 4) , Dorothee Gramatzki (1, 2) , Emilie Le Rhun (1, 2, 5, 6) , Jennifer Clarke (7) , Riccardo Soffietti (8) , Wolfgang Wick (9, 10) , Olivier Chinot (11, 12) , François Ducray (13, 14, 15) , Patrick Roth (1, 2) , Kerrie Mcdonald (16) , Peter Hau (17) , Andreas Hottinger (18) , Jaap Reijneveld (19, 20) , Oliver Schnell (21) , Christine Marosi (22) , Michael Glantz (23, 24) , Amélie Darlix (25, 26) , Giuseppe Lombardi (27) , Dietmar Krex (28, 29) , Martin Glas (30, 29) , David A Reardon (31, 32) , Martin van den Bent (33) , Florence Lefranc (34) , Ulrich Herrlinger (35) , Evangelia Razis (36) , Antoine F Carpentier (37, 38) , Samuel Phillips (7) , Roberta Rudà (8) , Antje Wick (10) , Emeline Tabouret (11, 12) , David Meyronet (13, 14, 15) , Claude-Alain Maurage (39) , Elisabeth Rushing (1) , Robert Rapkins (16) , Elisabeth Bumes (17) , Monika Hegi (18) , Astrid Weyerbrock (20) , Dawit Aregawi (23, 24) , Christian Gonzalez-Gomez (7) , Alessia Pellerino (8) , Martin Klein (19) , Matthias Preusser (22) , Martin Bendszus (40) , Vassilis Golfinopoulos (41) , Andreas von Deimling (40, 9) , Thierry Gorlia (41) , Patrick Wen (31, 32) , Guido Reifenberger (3, 4) , Michael Weller (1, 2)
1 University hospital of Zurich [Zurich]
2 UZH - Universität Zürich [Zürich] = University of Zurich
3 Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]
4 University Hospital Düsseldorf
5 Département de Neurochirurgie[Lille]
6 PRISM - Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192
7 UC San Francisco - University of California [San Francisco]
8 Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino
9 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
10 Universität Heidelberg [Heidelberg] = Heidelberg University
11 INP - Institut de neurophysiopathologie
12 Neuro-Oncologie [Hôpital de la Timone - APHM]
13 UCBL - Université Claude Bernard Lyon 1
14 HCL - Hospices Civils de Lyon
15 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
16 UNSW - University of New South Wales [Sydney]
17 University Hospital Regensburg
18 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
19 VUMC - Vrije Universiteit Medical Centre
20 SEIN - Stichting Epilepsie Instellingen Nederland
21 Uniklinik - Universitäts Klinikum Freiburg = University Medical Center Freiburg
22 Medizinische Universität Wien = Medical University of Vienna
23 Penn State College of Medicine
24 Penn State Health Milton S. Hershey Medical Center
25 IGF - Institut de Génomique Fonctionnelle
26 ICM - Institut régional de Cancérologie de Montpellier
27 Veneto Institute of Oncology IOV-IRCCS [Padua, Italy]
28 University Hospital Carl Gustav Carus [Dresden, Germany]
29 DKTK - German Cancer Consortium [Heidelberg]
30 University of Duisbourg-Essen
31 Dana-Farber Cancer Institute [Boston]
32 HMS - Harvard Medical School [Boston]
33 Erasmus MC - Erasmus University Medical Center [Rotterdam]
34 Hôpital Universitaire de Bruxelles
35 University Hospital Bonn
36 Hygeia Hospital
37 AP-HP - Hopital Saint-Louis [AP-HP]
38 UPCité - Université Paris Cité
39 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
40 Heidelberg University Hospital [Heidelberg]
41 EORTC - European Organisation for Research and Treatment of Cancer [Bruxelles]
Caroline Hertler
University hospital of Zurich [Zurich]
Universität Zürich [Zürich] = University of Zurich
Jörg Felsberg
  • Fonction : Auteur
Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]
University Hospital Düsseldorf
Dorothee Gramatzki
University hospital of Zurich [Zurich]
Universität Zürich [Zürich] = University of Zurich
Emilie Le Rhun
University hospital of Zurich [Zurich]
Universität Zürich [Zürich] = University of Zurich
Département de Neurochirurgie[Lille]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192
Jennifer Clarke
University of California [San Francisco]
Riccardo Soffietti
Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino
Wolfgang Wick
German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
Universität Heidelberg [Heidelberg] = Heidelberg University
Olivier Chinot
Institut de neurophysiopathologie
Neuro-Oncologie [Hôpital de la Timone - APHM]
François Ducray
Université Claude Bernard Lyon 1
Hospices Civils de Lyon
Centre de Recherche en Cancérologie de Lyon
Patrick Roth
  • Fonction : Auteur
University hospital of Zurich [Zurich]
Universität Zürich [Zürich] = University of Zurich
Kerrie Mcdonald
  • Fonction : Auteur
University of New South Wales [Sydney]
Peter Hau
  • Fonction : Auteur
University Hospital Regensburg
Andreas Hottinger
  • Fonction : Auteur
Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
Jaap Reijneveld
  • Fonction : Auteur
Vrije Universiteit Medical Centre
Stichting Epilepsie Instellingen Nederland
Oliver Schnell
Universitäts Klinikum Freiburg = University Medical Center Freiburg
Christine Marosi
  • Fonction : Auteur
  • PersonId : 899740
Medizinische Universität Wien = Medical University of Vienna
Michael Glantz
  • Fonction : Auteur
Penn State College of Medicine
Penn State Health Milton S. Hershey Medical Center
Amélie Darlix
Institut de Génomique Fonctionnelle
Institut régional de Cancérologie de Montpellier
Giuseppe Lombardi
Veneto Institute of Oncology IOV-IRCCS [Padua, Italy]
Dietmar Krex
  • Fonction : Auteur
University Hospital Carl Gustav Carus [Dresden, Germany]
German Cancer Consortium [Heidelberg]
Martin Glas
  • Fonction : Auteur
University of Duisbourg-Essen
German Cancer Consortium [Heidelberg]
David A Reardon
  • Fonction : Auteur
Dana-Farber Cancer Institute [Boston]
Harvard Medical School [Boston]
Martin van den Bent
Erasmus University Medical Center [Rotterdam]
Florence Lefranc
  • Fonction : Auteur
  • PersonId : 1077548
Hôpital Universitaire de Bruxelles
Ulrich Herrlinger
University Hospital Bonn
Evangelia Razis
  • Fonction : Auteur
Hygeia Hospital
Antoine F Carpentier
Hopital Saint-Louis [AP-HP]
Université Paris Cité
Samuel Phillips
  • Fonction : Auteur
University of California [San Francisco]
Roberta Rudà
  • Fonction : Auteur
Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino
Antje Wick
  • Fonction : Auteur
Universität Heidelberg [Heidelberg] = Heidelberg University
Emeline Tabouret
Institut de neurophysiopathologie
Neuro-Oncologie [Hôpital de la Timone - APHM]
David Meyronet
Université Claude Bernard Lyon 1
Hospices Civils de Lyon
Centre de Recherche en Cancérologie de Lyon
Claude-Alain Maurage
  • Fonction : Auteur
Centre Hospitalier Régional Universitaire [CHU Lille]
Elisabeth Rushing
University hospital of Zurich [Zurich]
Robert Rapkins
University of New South Wales [Sydney]
Elisabeth Bumes
University Hospital Regensburg
Monika Hegi
Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
Astrid Weyerbrock
Stichting Epilepsie Instellingen Nederland
Dawit Aregawi
  • Fonction : Auteur
Penn State College of Medicine
Penn State Health Milton S. Hershey Medical Center
Christian Gonzalez-Gomez
  • Fonction : Auteur
University of California [San Francisco]
Alessia Pellerino
Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino
Martin Klein
Vrije Universiteit Medical Centre
Matthias Preusser
Medizinische Universität Wien = Medical University of Vienna
Martin Bendszus
Heidelberg University Hospital [Heidelberg]
Vassilis Golfinopoulos
European Organisation for Research and Treatment of Cancer [Bruxelles]
Andreas von Deimling
Heidelberg University Hospital [Heidelberg]
German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
Thierry Gorlia
  • Fonction : Auteur
European Organisation for Research and Treatment of Cancer [Bruxelles]
Patrick Wen
Dana-Farber Cancer Institute [Boston]
Harvard Medical School [Boston]
Guido Reifenberger
  • Fonction : Auteur
Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]
University Hospital Düsseldorf
Michael Weller
University hospital of Zurich [Zurich]
Universität Zürich [Zürich] = University of Zurich

Résumé

Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24–78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival 2 C. Hertler et al. / European Journal of Cancer 189 (2023) 112913 was 9.9 years (95% confidence interval [95% CI] 7.9–11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. Conclusions: Freedom from progression is a powerful predictor of overall survival in longterm survivors with glioblastoma. Patients without relapse often have MGMT promoterunmethylated glioblastoma and may represent a distinct subtype of glioblastoma

Domaines

Sciences du Vivant [q-bio]
Fichier principal
Vignette du fichier
1-s2.0-S0959804923002307-main.pdf (1.57 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence
Paternité

Camille Dubernet  : Connectez-vous pour contacter le contributeur

https://hal.science/hal-04207063

Soumis le : mercredi 25 septembre 2024-14:05:24

Dernière modification le : vendredi 27 septembre 2024-03:25:41

Télécharger pour visualiser

Dates et versions

hal-04207063 , version 1 (25-09-2024)

Licence

Paternité

Identifiants

Citer

Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, Emilie Le Rhun, Jennifer Clarke, et al.. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419). European Journal of Cancer, 2023, 189, pp.112913. ⟨10.1016/j.ejca.2023.05.002⟩. ⟨hal-04207063⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

HCL CNRS UNIV-AMU UNIV-LYON1 IGF BS UNIV-MONTPELLIER INP CRCL INP-GLIOME UNIV-LILLE UDL NEUROMARSEILLE
60 Consultations
12 Téléchargements

Altmetric

Partager

More